Tiziana Life Sciences PLC   | AIM:TILS


LEADERSHIP Team


SENIOR MANAGEMENT


Gabriele Cerrone MBA               Executive Chairman

Mr Cerrone has a successful track record and extensive experience in the financing and restructuring of micro-cap biotechnology companies.  He has founded nine biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has taken six of these companies to the NASDAQ Market and one to the AIM Market in London.  Mr Cerrone co-founded Trovagene, Inc. (NASDAQ: TROV), a molecular diagnostic company and served as its Co-Chairman; he was a co-founder and served as Chairman of both Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) and Callisto Pharmaceuticals, Inc. (OTCMKTS: CLSP), and was a Director of and led the restructuring of Siga Technologies, Inc. (NASDAQ: SIGA).  Mr Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007 with Inhibitex, Inc.  Mr Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb Co in 2012.

Mr Cerrone is the Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology using microRNA technology; Chairman and Founder of Tiziana Life Sciences plc (AIM: TILS) an oncology focused therapeutics company; Chairman and Co-Founder of Rasna Therapeutics Limited, a company focused on the development of therapeutics for leukaemias; Co-Founder of ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV); and founder of BioVitas Capital Ltd.



James Tripp    Chief Operating Officer and Head of Global Clinical Operations

Mr. Tripp is responsible for all operations, including global clinical development.  Mr. Tripp is a global bio/pharmaceutical executive with over twenty years' experience in biopharmaceutical operations and clinical R&D management. He has been involved in all phases of drug development from discovery through commercialization.  He started his career in pharmaceuticals while attending Harvard School of Public Health and at Massachusetts General Hospital in Boston, MA. 

He was previously Director, Clinical Management at Novo Nordisk, A/S, where he managed the US project teams overseeing the insulin/GLP-1, Victoza®, and Saxenda® portfolios. Prior to Novo Nordisk, Mr. Tripp was Associate Director at Regeneron Pharmaceuticals (REGN:Nasdaq) where he started as a Therapeutic Area Project Manager (TAPM) for inflammation programs, focusing on developing IL-1 Trap (now Arcalyst®) and then creating and heading up the Clinical Compliance & Training group for the Clinical & Project Management Office. Earlier Mr. Tripp has also had roles on both Nasonex® and Clarinex® as Operations Leader at Schering-Plough (now Merck) and overseeing global trials and managing the successful co-development collaborations with GSK, while at Bayer Pharmaceuticals on Baycol®, and while at Hoffman-La Roche on Boniva®.



Tiziano Lazzaretti MBA   Chief Financial Officer

Mr Lazzaretti has extensive experience in the healthcare and pharmaceutical industry and joins Tiziana from Pharmentis Srl, an Italian pharmaceutical business, where he served as Group Finance Director since 2011. Prior to this, Mr Lazzaretti held senior roles at Alliance Boots Healthcare, Accenture and other listed companies such as SNIA Spa and Fiat Group.

Mr Lazzaretti has a Bachelor of Science (BSc hons) in Accounting and Finance from the University of Turin, Italy and was awarded a Master in Business Administration (MBA) from Bocconi University, Milan.



Robert Evans PharmD   VP, Clinical Sciences

Dr. Evans joined Tiziana Life Sciences in April 2016 as Vice President of Clinical Sciences. Prior to joining the Company, Dr. Evans served as Vice President of Clinical Development at Glenmark Pharmaceuticals, Inc. and was responsible for providing project and clinical leadership across multiple programs focused on the treatment of oncology, respiratory and dermatology disorders. Prior to Glenmark, Dr. Evans served in scientific leadership roles in the Immunology and Inflammation Group at Regeneron Pharmaceutical.

Dr. Evans received his Bachelor of Science degree in Pharmacy from the University of Illinois, and a PharmD from the University of Kansas City, Kansas City Missouri. He completed Fellowships at St Jude Children's Research Hospital and the University of Pittsburgh. Dr. Evans is the author or co-author of numerous peer-reviewed journal articles, abstracts and scientific publications.





Scientific Founders


Andrea Brancale PhD               Computational Chemistry

Andrea is currently Senior Lecturer in Medical Chemistry, School of Pharmacy and Pharmaceutical Sciences at Cardiff University. Since his appointment to lecturer in 2002 at the Welsh School of Pharmacy (now the Cardiff School of Pharmacy and Pharmaceutical Sciences), Andrea has built an international reputation as an expert in the area of computer-based drug design. He obtained his PhD in 2001 in synthetic medical chemistry under Professor Chris McGuigan and following on from his PhD he worked as a PostDoctoral Fellow on a GSK-sponsored research project on the novel pre-nucleoside analogues as anti-HIV agents. Andrea's main research programs are currently oriented towards the in silico design of anticancer and antiviral compounds. He is author on more than 100 publications, which include original papers in high impact scientific journals and conference proceedings. In 2013 he was the recipient of the William Prusoff young investigator award for his contribution to the antiviral field. He was the Chemistry Editor of Antiviral Chemistry and Chemotherapy and is a Board member of the International Society for Antiviral Research. Andrea sits on the Clinical Advisory Board of Synergy Pharmaceuticals, a biopharmaceutical company focused on the development of novel drugs for the treatment of gastrointestinal diseases and disorders.



Richard Clarkson PhD               Cancer Biology

Richard is a senior lecturer in translational cancer research at the University of Cardiff School of Biosciences and is one of four inaugural senior academics at the recently launched European Cancer Research Institute in Cardiff. He was trained in Biological Sciences at Leicester University (BSc Hons) and immunogenetics in the Faculty of Medicine, Manchester University (PhD). He undertook his post-doctoral research in Australia and at Edinburgh University before taking up two Research Fellowships at Cambridge University, then moving to Cardiff in 2005 as an RC-UK research fellow in translational research. His expertise is in cell and molecular biology – particularly the genetic regulation of cell fate and tissue (cellular) architecture in mammalian tissues. His move from Cambridge to Cardiff coincided with a shift in research emphasis towards the aetiology and molecular targeting of cancer, taking what he had learned above the genes that regulate mammary tissue homeostasis in the mouse to the pathology of breast cancer. Key skills include molecular biology of cancer, gene expression analysis and transgenics. Today he runs a team of researchers that focus on two key drivers of metastatic breast cancer: cell migration and cancer stem cells. He has more than 40 articles in international biomedical journals and is a regular speaker at international conferences. 



Andrew Westwell PhD               Drug Design

Andrew is currently Reader in Medicinal Chemistry at the School of Pharmacy and Pharmaceutical Sciences at Cardiff University, having worked in Cardiff since 2006. He received his BSc (Hons) in Chemistry and PhD in organic chemistry at the University of Leeds. Following a postdoctoral fellowship at Loughborough University, he joined a Cancer Research UK Programme at the University of Nottingham, initially as Senior Research Fellow, later as Lecturer. Following his move to Cardiff he has established a number of collaborative research projects focusing on breast cancer drug discovery, new synthetic chemistry methods, and cancer imaging by Positron Emission Tomography. He has published more than 100 journal articles and reviews. Technology transfer activities have included a number of patent filings, and he was lead chemist in Nottingham on the development of a new molecule from discovery at the bench to early clinical evaluation. Other recent research related activities have included serving as Honorary Treasurer of the British Association for Cancer Research (2007-2012). He currently serves on the Editorial Board of the international journal Future Medicinal Chemistry.



 

Management Team


Gabriele Cerrone MBA

James Tripp

Tiziano Lazzaretti MBA

Robert Evans PharmD



Scientific Founders


Andrea Brancale PhD

Richard Clarkson PhD   

Andrew Westwell PhD



Board of Directors


Gabriele Cerrone MBA, Chairman

Riccardo Dalla-Favera MD, Director

Kunwar Shailubhai, PhD MBA Director

Willy Simon, Non-Executive Director



Scientific Advisory Committee


Prof. Napoleone Ferrara MD

Prof. Pier Paolo Di Fiore MD PhD

Dr Thomas Adams  PhD

Prof. Roberto Pellicciari  PhD

Prof. Kevan Herold MD

Prof. Howard Weiner MD